microRNAs通过Hippo通路抑制肝细胞癌发生的研究进展

doi:10.16352/j.issn.1001-6325.2023.12.1871

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (12): 1871-1875.doi: 10.16352/j.issn.1001-6325.2023.12.1871

microRNAs通过Hippo通路抑制肝细胞癌发生的研究进展

查娜¹, 郝丹丹², 李天柱^3*

1.赤峰学院附属医院肿瘤内科,内蒙古赤峰 024000;
赤峰学院基础医学院 2.生理学教研室;
3.分子医学研究中心, 内蒙古赤峰 024000

收稿日期:2022-10-02 修回日期:2023-04-10 出版日期:2023-12-05 发布日期:2023-11-29
通讯作者: ^* litianzhu2016@163.com
基金资助:
国家自然科学基金(82060118);内蒙古自治区高等学校科学研究项目(NJZY20203);赤峰学院青年科技英才项目(CFXYYT2202);内蒙古自然科学基金 (2022MS08032)

Research progress of microRNAs suppressing tumorigenesis through Hippo signaling

CHA Na¹, HAO Dandan², LI Tianzhu^3*

1. Department of Oncology, the Affiliated Hospital of Chifeng University, Chifeng 024000;
2. Department of Physiology;
3. Molecular Medicine Research Center, School of Basic Medical Science, Chifeng University, Chifeng 024000, China

Received:2022-10-02 Revised:2023-04-10 Online:2023-12-05 Published:2023-11-29
Contact: ^* litianzhu2016@163.com

摘要/Abstract

摘要： Hippo信号通路下游效应器蛋白Yes相关蛋白(YAP)和转录辅助激活因子(TAZ)的异常激活参与肝细胞癌(HCC)恶性进展。微小RNA(miRNAs)作为抑癌基因通过Hippo YAP/TAZ信号影响HCC增殖、迁移和凋亡等途径调控HCC恶性生物学表型。探索miRNAs 调节Hippo YAP/TAZ通路在HCC中的作用可为诊断和治疗HCC提供新的思路。

关键词: 肝细胞癌, Hippo通路, 微小RNA, 分子机制

Abstract: The aberrant activation of yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), downstream effectors of the Hippo signaling pathway, has been implicated in hepatocellular carcinoma(HCC). The microRNAs (miRNAs) works as a tumor suppressors that influence the proliferation, migration and apoptosis of tumor cells by modulating Hippo-YAP/TAZ signaling during hepatic tumorigenesis. Exploring the role of miRNAs in regulating Hippo YAP/TAZ pathway in HCC can provide new ideas for the diagnosis and treatment of HCC.

Key words: hepatocellular carcinoma, Hippo pathway, microRNAs, molecular mechanism

中图分类号:

R735.7

查娜, 郝丹丹, 李天柱. microRNAs通过Hippo通路抑制肝细胞癌发生的研究进展[J]. 基础医学与临床, 2023, 43(12): 1871-1875.

CHA Na, HAO Dandan, LI Tianzhu. Research progress of microRNAs suppressing tumorigenesis through Hippo signaling[J]. Basic & Clinical Medicine, 2023, 43(12): 1871-1875.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2023.12.1871

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2023/V43/I12/1871

参考文献 25

[1]	Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021,71:209-249.
[2]	Hayashi H, Higashi T, Yokoyama N, et al. An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression[J]. Cancer Res, 2015,75:4985-4997.
[3]	Wang T, Qin ZY, Wen LZ, et al. Epigenetic restriction of Hippo signaling by MORC2 underlies stemness of hepatocellular carcinoma cells[J]. Cell Death Differ, 2018,25:2086-2100.
[4]	Chen M, Wu L, Tu J, et al. miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression[J]. EBioMedicine, 2018,35:142-154.
[5]	Xie SC, Zhang JQ, Jiang XL, et al. LncRNA CRNDE facilitates epigenetic suppression of CELF2 and LATS2 to promote proliferation, migration and chemoresistance in hepatocellular carcinoma[J]. Cell Death Dis, 2020,11:676. doi:10.1038/s41419-020-02853-8.
[6]	Gao R, Kalathur R, Coto-Llerena M, et al. YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis[J]. EMBO Mol Med, 2021,13:e14351. doi:10.15252/emmm.202114351.
[7]	Qin Y, Pei Z, Feng Z, et al. Oncogenic activation of YAP signaling sensitizes ferroptosis of hepatocellular carcinoma via ALOXE3-mediated lipid peroxidation accumulation[J]. Front Cell Dev Biol, 2021,9:751593. doi:10.3389/fcell.2021.751593.
[8]	Zhou Y, Wang Y, Zhou W, et al. YAP promotes multi-drug resistance and inhibits autophagy-related cell death in hepatocellular carcinoma via the RAC1-ROS-mTOR pathway[J]. Cancer Cell Int, 2019,19:179. doi:10.1186/s12935-019-0898-7.
[9]	Zhang H, Yu QL, Meng L, et al. TAZ-regulated expression of IL-8 is involved in chemoresistance of hepato-cellular carcinoma cells[J]. Arch Biochem Biophys, 2020,693:108571. doi:10.1016/j.abb.2020.108571.
[10]	Sun T, Mao W, Peng H, et al. YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin[J]. Cell Oncol (Dordr), 2021,44:689-699.
[11]	张春艳, 张富春, 马纪, 等. microRNA与肝癌[J]. 基础医学与临床, 2016,36:1429-1432
[12]	Liu AM, Poon RT, Luk JM. MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties[J]. Biochem Biophys Res Commun, 2010,394:623-627.
[13]	Ruan T, He X, Yu J, et al. MicroRNA-186 targets Yes-associated protein 1 to inhibit Hippo signaling and tumorigenesis in hepatocellular carcinoma[J]. Oncol Lett, 2016,11:2941-2945.
[14]	Makino Y, Hikita H, Kodama T, et al. CTGF mediates tumor-stroma interactions between hepatoma cells and hepatic stellate cells to accelerate HCC progression[J]. Cancer Res, 2018,78:4902-4914.
[15]	Wang Y, Cui M, Sun BD, et al. MiR-506 suppresses proliferation of hepatoma cells through targeting YAP mRNA 3′UTR[J]. Acta Pharmacol Sin, 2014,35:1207-1214.
[16]	Lei CJ, Li L, Gao X, et al. Hsa-miR-132 inhibits proliferation of hepatic carcinoma cells by targeting YAP[J]. Cell Biochem Funct, 2015,33:326-333.
[17]	Lei CJ, Yao C, Li DK, et al. Effect of co-transfection of miR-520c-3p and miR-132 on proliferation and apoptosis of hepatocellular carcinoma Huh7[J]. Asian Pac J Trop Med, 2016,9:898-902.
[18]	Zhang L, Yu Z, Xian Y, et al. microRNA-497 inhibits cell proliferation and induces apoptosis by targeting YAP1 in human hepatocellular carcinoma[J]. FEBS Open Bio, 2016,6:155-164.
[19]	Higashi T, Hayashi H, Ishimoto T, et al. miR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in hepatocellular carcinoma cells[J]. Br J Cancer, 2015,113:252-258.
[20]	Li J, Fang L, Yu W, et al. MicroRNA-125b suppresses the migration and invasion of hepatocellular carcinoma cells by targeting transcriptional coactivator with PDZ-binding motif[J]. Oncol Lett, 2015,9:1971-1975.
[21]	Liu P, Zhang H, Liang X, et al. HBV preS2 promotes the expression of TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular carcinoma[J]. Oncotarget, 2015,6:29048-29059.
[22]	He Y, Hwang S, Cai Y, et al. MicroRNA-223 amelio-rates nonalcoholic steatohepatitis and cancer by targeting multiple inflammatory and oncogenic genes in hepatocytes[J]. Hepatology, 2019,70:1150-1167.
[23]	Yang X, Yin J, Yu J, et al. miRNA-195 sensitizes human hepatocellular carcinoma cells to 5-FU by targeting BCL-w[J]. Oncol Rep, 2012,27:250-257.
[24]	Yang X, Yu J, Yin J, et al. MiR-195 regulates cell apoptosis of human hepatocellular carcinoma cells by targeting LATS2[J]. Pharmazie, 2012,67:645-651
[25]	Wu H, Zhang W, Wu Z, et al. miR-29c-3p regulates DNMT3B and LATS1 methylation to inhibit tumor progression in hepatocellular carcinoma[J]. Cell Death Dis, 2019,10:48. doi:10.1038/s41419-018-1281-7.

microRNAs通过Hippo通路抑制肝细胞癌发生的研究进展

Research progress of microRNAs suppressing tumorigenesis through Hippo signaling

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 15

编辑推荐

Metrics

本文评价

[1]	依马木买买提江·阿布拉, 帕哈尔丁·白克热, 易超, 佟庆. 血浆hsa_circ_005230在原发性肝细胞癌诊断和预后评估中的临床价值[J]. 基础医学与临床, 2023, 43(9): 1417-1422.
[2]	韩晶晶, 王萱若, 张欣怡, 高涵, 成秀梅, 杨留才, 曲学彬. 转录因子CREB调节小鼠CD4⁺淋巴细胞中miR-30a的表达[J]. 基础医学与临床, 2023, 43(8): 1229-1233.
[3]	林映雪, 崔海鹏, 王爱国, 姚银辉, 赵娟. 雷帕霉素减缓转基因小鼠肝细胞癌进展[J]. 基础医学与临床, 2023, 43(8): 1241-1246.
[4]	王帆, 邓勇志. 微小RNAs在心肌肥厚中作用和分子机制的研究进展[J]. 基础医学与临床, 2023, 43(7): 1167-1170.
[5]	邹瑾, 何向蕾, 张欣, 陈日萍, 张宇, 胡帅悦, 应士波. 蛋白质精氨酸残基化学修饰酶PADs与PRMTs在人肝癌细胞系中的表达[J]. 基础医学与临床, 2023, 43(6): 898-903.
[6]	冀梦蝶, 苑赞, 卞晓翠, 杨玉容, 郭鑫, 王琦, 陈阳. 人肝癌细胞系HepG2和Huh7中的基因组拷贝数变异分析[J]. 基础医学与临床, 2023, 43(6): 960-966.
[7]	鲁益朦, 谭季春. 宫腔粘连发病的分子机制研究进展[J]. 基础医学与临床, 2023, 43(4): 547-553.
[8]	杨孟迪, 丁雨露, 王玉洁, 何风英, 孙琳楠, 甄东户. MicroRNA在糖尿病性骨质疏松症中作用的研究进展[J]. 基础医学与临床, 2023, 43(2): 311-316.
[9]	刘爱霞, 张浩, 孙杰, 杨丽华, 赵晓涛. GPS2对肝癌细胞系MHCC-97H增殖、迁移与侵袭的调控作用[J]. 基础医学与临床, 2023, 43(12): 1784-1791.
[10]	马聪聪, 刘洋, 吕洋, 王海萍. 线粒体自噬在心肌缺血/再灌注损伤中的作用研究进展[J]. 基础医学与临床, 2023, 43(11): 1723-1727.
[11]	黄驿胜, 叶启文, 王竞枫. miR-203a-3p抑制人肝癌细胞系增殖[J]. 基础医学与临床, 2023, 43(1): 87-94.
[12]	邱立彬, 张新才, 赵倩. LncRNA DANCR靶向miR-3646减轻缺氧诱导的大鼠心肌细胞系H9c2的损伤[J]. 基础医学与临床, 2023, 43(1): 144-151.
[13]	阮锋, 李贺伟, 龚艳琳, 刘佳丽, 刘平. 过表达miR-217调控EZH2促进骨质疏松模型小鼠BM-MSCs成骨分化[J]. 基础医学与临床, 2022, 42(9): 1406-1413.
[14]	赵钰珊, 冀梦蝶, 董昱诚, 郭鑫, 宋博渊, 陈阳. 肝细胞癌中EZH2基因相关的表观遗传调控机制[J]. 基础医学与临床, 2022, 42(6): 864-870.
[15]	王玉敏, 陈济超, 王洪权, 王金华, 唐博. MicroRNAs靶向脂代谢重编程参与肝细胞癌发生的研究进展[J]. 基础医学与临床, 2022, 42(12): 1930-1934.